Oppenheimer & Co’s Sonoma Pharmaceuticals SNOA Stock Holding History

Oppenheimer & Co’s Portfolio SNOA Stock Details SNOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-44	Closed	-$139K	–	1466
2013 Q4	$139K	Buy	+44	New	+$117K	﹤0.01%	1269

Other funds holding SNOA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return

NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Oppenheimer & Co's SNOA Position: Q1 2014 in Review

Oppenheimer & Co sold out of Sonoma Pharmaceuticals (SNOA) in Q1 2014, closing a stake of 44 shares — an estimated $139K sold.

Oppenheimer & Co first reported a position in SNOA in Q4 2013 and held it in 1 quarter. The position peaked at $139K in Q4 2013. 18 funds tracked by Wall St. Rank hold SNOA as of Q1 2014.

Oppenheimer & Co reported no remaining Sonoma Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
Oppenheimer & Co sold 44 Sonoma Pharmaceuticals shares in Q1 2014, an estimated $139K.
Oppenheimer & Co first reported a position in Sonoma Pharmaceuticals in Q4 2013 and held it in 1 quarter.
Oppenheimer & Co's Sonoma Pharmaceuticals position peaked at $139K in Q4 2013.
18 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q1 2014.

Based on Oppenheimer & Co's 13F filing for Q1 2014, filed 9 May 2014.